Resume hydroxychloroquine trials as Lancet's study incorrect: CSIR, others

It also stated that the decision of WHO to temporarily suspend quality HCQ trials based on findings of the Lancet study appears to be a "knee-jerk reaction"

Council of Scientific and Industrial Research (CSIR) Director-General Shekhar Mande, Institute of Genomics and Integrative Biology (IGIB) Delhi Director Anurag Agarwal and Chennai Mathematical Institute (CMI) Chennai Director Rajeev Karandikar have written to the World Health Organisation (WHO) and asked the global health body to resume trial of hydroxychloroquine (HCQ) for the treatment of Covid-19 patients as early as possible, asserting that the Lancet's study is not correct.

In an email to Lancet paper editor Richard Charles Horton and WHO, Mande stated the study published in Lancet on HCQ and chloroquine and its effect on Covid-19 is an observational study